FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Krogulski Kenneth</u>			2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]								5. Relationship of (Check all applica X Director		licable) tor	10%	Owner
(Last) (First) (Middle) 1600 WEST END AVE., SUITE 1300	, SUITE 1300			3. Date of Earliest Transaction (Month/Day/Year) 11/16/2023								below	er (give title	below	(specify
(Street) NASHVILLE TN 37203			4. If Amendment, Date of Original Filed (Month/Day/Year) 11/30/2023								Individual or Joint/Group Filing (Chiline) X Form filed by One Reporting Form filed by More than One Person			e Reporting Pe	rson
(City) (State) (Zip)		Rul	Rule 10b5-1(c) Transaction Indication												
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Nor	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of,	or B	enefic	ially	Own	ed		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Exe if an	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr. 5)			3, 4 and 8		unt of ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock	11/16/2023					L	V	66(1)	A	\$1	.73	227,925		D	
Common Stock	11/17/2023				L	V	280(1)	A	\$1	\$1.83		8,205	D		
Common Stock	11/20/2023				L	V	268(1)	A	\$1	\$1.7		8,473	D		
Common Stock	11/21/2023					L	V	125(1)	A	\$1	\$1.76		8,598	D	
Common Stock	11/22/2023					L	V	280(1)	A	\$1	\$1.74		8,878	D	
ommon Stock 11/27/2023		2023)23			L V		379(1)	1) A		\$1.86		9,257	D	
Common Stock	11/28/2023					L	V	124(1)	A	\$1	.68	229,381		D	
Common Stock	11/29/2023					L	V	165(1)	A	\$1	.73	22	9,546	D	
Common Stock	11/30/2023					L	V	324 ⁽¹⁾	A \$.66	229,870		D	
Table II -								osed of, o				Owned	t		
1. Title of Derivative Conversion or Exercise Price of Derivative Security (Instr. 3) 2.				tion of		6. Date Exerci Expiration Da (Month/Day/Yo		te	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Dei	Price of rivative curity str. 5)	ve derivative Securities	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
Explanation of Responses:		Code	v	(A)		Date Exercisa	able	Expiration Date		Amount or Number of Shares					

1. The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.

Remarks:

Kenneth J. Krogulski by /s/ John Hamm as attorney-infact

** Signature of Reporting Person

12/06/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).